secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001140361-25-023261
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics reports FY2025 net loss of $9.6M; NDA for GTx-104 on track for June 2025 submission
--------------------------------------------------------------------------------

- Net loss of $9.6M ($0.79 per share) vs $12.9M ($1.35) in FY2024, decrease driven by change in warrant liabilities.
- R&D expenses rose to $9.5M (FY2024: $4.7M) due to the STRIVE-ON Phase 3 trial; cash at $22.1M.
- NDA for GTx-104 for aSAH expected to be submitted to FDA by end of June 2025 following positive Type C meeting.
- Secured $15M upfront private placement (led by Nantahala Capital, ADAR1 Partners) with potential $15M from warrants.
- STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/0001140361-25-023261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/ef20050698_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-023261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer